Priority Lists
Protocol Posting of
Activations
Closures
Temporary Closure Notice and Memorandum
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
| Closure Date | 2002-07-18 |
Permanent Closure Notice
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients with Locally Advanced Unresected Pancreatic Adenocarcinoma
| Study Coordinator(s) | William H. Isacoff, M.D. |
| Participants | Members, NCORP |
| Closure Date | 2001-06-19 |
Permanent Closure
Positron Emission Tomography (PET) Imaging of Lung Cancer Response to Therapy in Patients Registered to S9900
| Study Coordinator(s) | Anthony Shields, M.D.,Ph.D., Paul A. Bunn Jr., M.D., Wilbur A. Franklin, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, Surgeons, NCORP |
| Closure Date | 2001-05-15 |
Permanent Closure Notice and Memorandum
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Pancreas Cancer.
| Study Coordinator(s) | John S. Macdonald, M.D., Robert P. Whitehead, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
| Closure Date | 2001-06-01 |
Permanent Closure
A Phase II Trial of Antiandrogen Withdrawal In Patients with Progressive Prostate Cancer
| Study Coordinator(s) | A. Oliver Sartor, M.D., Mario A. Eisenberger, M.D., E. David Crawford, M.D., Maha H.A. Hussain, M.D. |
| Participants | UCOP, Medical Oncologists, Surgeons, Pathologists, NCORP, Members |
| Closure Date | 2001-06-01 |
Amendments, Revisions, Memoranda
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paciltaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP, Surgeons |
A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
| Study Coordinator(s) | Silvana Martino, D.O. |
Revision #1
A Phase II Study of Gemcitabine Plus Irinotecan (CPT-11) In Patients With Esophageal Cancer.
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #12
Phase III Randomized Trial of 12 Months VS 3 Months of Paclitaxel in Patients with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy (Intergroup)
| Study Coordinator(s) | Maurie Markman, M.D., Bradley J. Monk, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Pathologists, Surgeons, GOG, NCORP |
Long Term Follow-Up Protocol: An Administrative Tool.
| Participants | Members, NCORP, UCOP |
Revision #2
A Phase II Study of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach.
| Study Coordinator(s) | James H. Doroshow, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP |
Memorandum
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
A Phase II Trial of CVAD/Verapamil/Quinine for Treatment of Non-Hodgkin's Lymphoma
| Study Coordinator(s) | Thomas P. Miller, M.D. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required